How practical assessment guides LUTS treatment

TReating Urinary symptoms in Men in Primary Healthcare

PLanning Appropriate Nocturia Evaluation and Treatment

Nocturia Evaluation & Treatment: Implementing Assessment, Consolidating Therapy

Urodynamics for Prostate Surgery: Randomised Evaluation of Assessment Methods

FUNDED BY






Marcus Drake

Professor of Neurological Urology Imperial College London



Sensation (NDV, SDV, Urgency) "Social reasons"



Storage

Voiding



Received: 30 April 2018

Accepted: 2 July 2018

DOI: 10.1002/nau.23768

SOUNDING BOARD



Fundamentals of terminology in lower urinary tract function

Marcus J. Drake^{1,2}


<u>Increased daytime frequency</u> (IDF) is the complaint by the patient who considers that he/she voids too often by day. There is no minimum voiding frequency serving as a threshold for the symptom, since it is highly subjective, and there is a wide overlap between normal and symptomatic.

Nocturia is waking at night to pass urine. If a person typically passes urine once per night, they should be documented as having nocturia even if it does not cause them impairment of quality of life.

"Day" and "night" for IDF and nocturia refer to the patient's sleeping pattern, not environmental daylight and night-time.

"Social reasons"

These symptoms may be LUTD, or physiological (excess free water or salt, or pathological (eg chronic kidney disease).



Storage

Voiding



<u>Urgency</u> is a sudden compelling desire to pass urine which is difficult to defer.

<u>OAB</u> is urgency, with or without urgency incontinence, usually with increased daytime frequency and nocturia.

Exclude other causes of similar symptoms, e.g. UTI

Sensation (NDV, SDV, Urgency)
"Social reasons"



Storage

Voiding







Treatment of lower urinary tract symptoms in men in primary care using a conservative intervention: cluster randomised controlled trial

Marcus J Drake, ¹ Jo Worthington, ² Jessica Frost, ² Emily Sanderson, ² Madeleine Cochrane, ² Nikki Cotterill, ³ Mandy Fader, ⁴ Lucy McGeagh, ⁵ Hashim Hashim, ⁶ Margaret Macaulay, ⁴ Jonathan Rees, ⁷ Luke A Robles, ⁸ Gordon Taylor, ⁹ Jodi Taylor, ² Matthew J Ridd, ¹⁰ Stephanie J MacNeill, ² Sian Noble, ¹¹ J Athene Lane²

BMJ. 2023 Nov 15:383:e075219. doi: 10.1136/bmj-2023-075219.

Background



- Urinary symptoms can include:
 - Increased urinary frequency
 - Nocturia (waking at night to pass urine)
 - Urgency
 - Incontinence
 - Sensation of incomplete emptying
- ➤ Half of men over 40 years old experience at least one urinary symptom

> Significant impact on quality of life for many men

NICE recommend....

Key symptom assessments



Conservative therapies

(e.g. fluid advice, bladder training, PFME)



- Prescription of medication
- > Inappropriate urological referral
 - Persistent symptoms

- Conservative therapies are first-line treatment of LUTS, yet there is a lack of evidence on effectiveness, just a small single centre RCT.
- NICE Clinical Guideline 97 recommended a multicentre RCT to determine effectiveness.
- The TRIUMPH study was funded by the UK National Institute of Heath Research (HTA 16/90/03).
- Objective: To determine whether a standardised and manualised intervention for LUTS delivered in primary care achieves superior symptomatic improvement versus usual care.

Can a standardised booklet providing conservative care, tailored by a nurse, achieve a superior symptom outcome to usual care?

TRIUMPH overview



- Design: 2-arm cluster RCT in 30 NHS General Practice sites in England.
- Participants: 1,077 adult men (≥18) with bothersome LUTS.

- 524 men consented at sites randomised (1:1 ratio) to the intervention arm (n=17) and 553 at sites in the usual care arm (n=12)

at sites in the usual care arm (n=13)

- Primary outcome IPSS 12 months post-participant consent
- Secondary outcomes; quality of life, urinary symptoms and LUTS perception, referrals to hospital, adverse events


The TRIUMPH standardised advice booklet for self-management of LUTS was developed with patient and expert input.

GPs or research nurses/ healthcare assistants directed participants to relevant sections following assessment (manualised element)

Follow-up contacts over 12 weeks to assist adherence



"Prevalent LUTS"





Baseline Data – balance across arms for all variables

	Intervention			Usual care	
	nª		n ^a		
Total number of participants; n		524		553	
Demographic characteristics					
Age (years); mean (SD) [min – max]	524	68.95 (9.27) [32 – 94]	553	68.44 (9.25) [30 – 95]	
Ethnicity; n(%) White Black/African/Caribbean/Black British Mixed/Multiple ethnic groups Asian/Asian British Other ethnic group	522	513 (98.28) 1 (0.19) 2 (0.38) 3 (0.57) 2 (0.38)	550	542 (98.55) 1 (0.18) 2 (0.36) 2 (0.36)	
Disclosure declined	F17	1 (0.19)	F42	3 (0.55)	
Marital status; n(%) Single Married Civil partnered Divorced Widowed Disclosure declined	517	21 (4.06) 429 (82.98) 7 (1.35) 31 (6.00) 27 (5.22) 2 (0.39)	543	25 (4.60) 440 (81.03) 15 (2.76) 32 (5.89) 28 (5.16) 3 (0.55)	
IMD score; median (IQR) [min – max]	506	8.80 (5.75, 13.71) [1.18 – 60.30]	525	9.89 (6.21, 15.45) [1.64 – 55.13]	
IMD quintile ; n(%) Quintile 1 (most deprived) Quintile 2 Quintile 3 Quintile 4 Quintile 5 (least deprived)	506	17 (3.36) 33 (6.52) 67 (13.24) 141 (27.87) 248 (49.01	525	21 (4.00) 37 (7.05) 106 (20.19) 136 (25.90) 225 (42.86)	
Total IPSS score; mean (SD) [min – max]	501	13.62 (5.83) [1, 33]	541	14.59 (6.58) [2, 34]	
IPSS QoL score; mean (SD) [min – max]	516	3.47 (1.19) [0, 6]	551	3.55 (1.13) [0, 6]	

Primary outcome: mean and difference in mean patientreported urinary symptom (IPSS) score at 12 months



	n	Mean	SD	Min - Max	Difference in means ^a	95% CI	•	Difference in means ^c	95% CI	p-value
Intervention	442	11.60	6.21	1 - 35	-1.81	(-2.66, -0.95)	< 0.001	-1.79	(-2.56, -	< 0.001
Usual care	473	13.88	6.84	0 - 32					1.01)	
Total N	915	12.78	6.64	0 - 35						
ICC (95% CI)					0.011 (0.001, 0.086)		0.004 (<0.001, 0.251)			

^a ITT analysis adjusted for baseline IPSS score and minimisation variables

- Difference in mean IPSS score at 12 months.
- The adjusted difference in means is -1.81 IPSS score points, 95% CI: (-2.66, -0.95).
- The MCID is thought to be 3.0 score points and the 95% confidence interval does not include this.

^c ITT analysis adjusted only for baseline IPSS score

Subgroup analyses



Interaction with treatment arm	N of participants in each level of subgroup	P-value	Interpretation
Nature of LUTS at baseline	Continuous ; Usual care; N=470	0.971	There is no evidence that there is
	Intervention; N=435		a difference in treatment effect in
Intervention delivery	TRIUMPH nurse; N= 249	0.387	any of the subgroups.
	Practice nurse; N= 190		
	Usual care; N=473		
Preferred method of contact	Phone; N= 310	0.245	
	Text; N= 13		
	Email; N= 108		
	Usual care; N=473		

Dose: Difference in mean IPSS compared to those who had no contact visits (usual care + those who didn't have follow-up contacts in intervention arm; N= 478 [473 + 5])	N of participants in each level of subgroup who provided IPSS at 12 months	Difference in means (95% CI)	p-value	Interpretation
One follow-up contact	5	-0.68 (-5.07, 3.70)	0.760	We do not have sufficient data to say
Two follow-up contact	25	-1.27 (-3.41, 0.86)	0.242	anything about treatment effect for those
Three follow-up contacts	407	-1.84 (-2.69, -0.99)	<0.001	who had one or two follow-up contacts. However, the results for those who had 3 follow-up contacts reflect the primary results

TRIUMPH conclusions

- This study developed an intervention which provides a practical resource to support symptom assessment and conservative treatment for LUTS in primary care.
- The TRIUMPH intervention showed a sustained benefit (one year) for men's LUTS and quality of life across a range of outcome measures in a UK primary care setting.
- Difference between treatment groups in mean IPSS score at 12 months is supported by all sensitivity analyses.
- Difference between treatment groups in mean ICIQ-UI-SF and IPSS QoL
- No evidence of a difference between treatment groups in the proportion of patients who had a referral to secondary care for urology.
- The numbers of adverse events were balanced across arms.
- A follow on impact study is introducing these materials into standard GP consultation systems to make them routinely available in all consultations.

EUROPEAN UROLOGY 62 (2012) 877-890



A Contemporary Assessment of Nocturia: Definition, Epidemiology, Pathophysiology, and Management—a Systematic Review and Meta-analysis

Jean-Nicolas Cornu ^{a,*}, Paul Abrams ^b, Christopher R. Chapple ^c, Roger R. Dmochowski ^d, Gary E. Lemack ^e, Martin C. Michel ^f, Andrea Tubaro ^g, Stephan Madersbacher ^h

Sleep disorders

Primary sleep disorders: insomnia, periodic leg movements, narcolepsy, arousal disorders (ie, sleepwalking, nightmares)
Secondary sleep disorders: cardiac failure, chronic obstructive pulmonary disease, endocrine disorders
Neurologic conditions: Parkinson disease, dementia, epilepsy

Psychiatric conditions: depression, anxiety

Chronic pain disorders

Alcohol or drug use (consumption or withdrawal)

Medications (corticosteroids, diuretics, β-adrenergic antagonists, thyroid hormones, psychotropics, antiepileptics)

Nocturnal polyuria

Peripheral edema/ANF secretion: Congestive heart failure, autonomic neuropathy, venous stasis, lymphostasis, hepatic failure, hypoalbuminemia/malnutrition,nephrotic syndrome

Excessive evening fluid intake

Nighttime drinking

Circadian defect in secretion or action of AVP (including CNS lesions of the hypothalamic-pituitary axis, Parkinson disease, MS)

Drugs: diuretics, ethanol, steroids

Renal tubular dysfunction (including diabetes mellitus and albuminuria)

Obstructive sleep apnea

No abnormality on FVC

NPI >20-33%

Nocturia

24-h urine volume >40 ml/kg

24-h polyuria

Diabetes mellitus Diabetes insipidus

Primary polydipsia

Hypercalcemia

Drugs (diuretics, selective serotonin reuptake inhibitors, calcium channel blockers, tetracycline, lithium, carbonic anhydrase inhibitors)

NBCi >0

Reduced bladder capacity (functional or extrinsic)

Bladder pain syndrome, BOO, OAB

Neurogenic bladder (Parkinson disease, MS, SCI, stroke)

Lower urinary tract cancer

Lower urinary tract calculi


Bladder aging

Voiding dysfunction with high postvoid residual

Cornu J-N et al. Eur Urol 2012

PLANET: What is the most appropriate way to assess and treat nocturia?

- For most cases of nocturia, simple advice and behavioural therapy is appropriate
- For some, a medical condition may be the cause
- GPs are often uncertain on the appropriate course of action
 - Referrals to urology, where specialist insight into medical causes is lacking
- Risk of poor treatment selection, cost and adverse outcomes
- How can the extensive scope of possible medical causes of nocturia be evaluated efficiently and effectively?



- Systematic reviews searching four databases (Jan 2000-April 2020), Expert/public consensus derived with Nominal Group Technique (NGT)
 - Endocrine/ Cardiovascular/ Renal (due to polyuria)
 - Sleep medicine/ Neurological (due to sleep disturbance or polyuria)
- Supplemented by already-published urological SRs to develop an Overarching Algorithm using expert/ public NGT consensus,









Evaluation and Treatment in Urology for Nocturia Caused by Nonurological Mechanisms: Guidance from the PLANET Study Matthew Smith a, Shoba Dawson a, Robert C. Andrews b, Sofia H. Eriksson c, Hugh Selsick d,

Matthew Smith", Shoba Dawson", Robert C. Andrews", Sofia H. Eriksson", Hugh Selsick", Andrew Skyrme-Jones^e, Udaya Udayaraj ^{f.g.}, Jonathan Rees^{f.}, Edward Strong^a, Emily J. Henderson ^{a,t}, Marcus J. Drake^{f.k.}

Results; general points

- Nocturia is a multifactorial symptom crossing many medical specialities
- Often there is no single reason easily identified for an individual patient
- The *medical history can be indicative, but an undiagnosed condition could be present* (e.g. obstructive sleep apnoea)
- Influence on nocturia can result from the condition, from the treatment or from insufficient control (e.g. peripheral oedema/ diuretics)
- Positive findings in one system (e.g. restless legs syndrome) should not end consideration of all systems
- Presence of a well-controlled condition (e.g. NIDDM) may be incidental rather than causative
- Rarely, nocturia is a screening opportunity (e.g. CKD), but this is not generally advocated, due to absence of supportive evidence

PLANET: Mechanisms underlying nocturia

Sleep

Neurological

Endocrine

Cardiovascular

Renal

Relative lightening of sleep Dysregulation of antidiuresis **Natriuresis Excessive water or salt intake** Salt and water retention **Nocturnal hypertension Nocturnal overfiltration** Impaired urine concentration Reduced bladder control

Smith M et al. Eur Urol Focus 2022;8:89-97

General treatment points

- 1. Fluid and diet advice
- 2. Sleep hygiene advice
- 3. Medication review. Review the timing and type of relevant medications

- Initial treatment may address the "predominant" cause of nocturia
- Any drug adjustment generally needs discussion with the prescriber
- Partnership is needed with the primary care physician

Specific treatment points

Sleep disorders; Primary care therapy of suspected *obstructive sleep apnoea* or *insomnia*


Cardiovascular; Primary care therapy of *hypertension* or suspected *cardiac failure*Renal; Primary care therapy of *CKD*

- Evening diuretic or anti-hypertensive can be trialled in exceptional circumstances **Endocrine system;** Correction of specific dysfunction
- Address any cause of excessive thirst (e.g. xerostomia)

Neurological; Improve circumstances that may affect reaching the toilet. Physiotherapy or occupational therapy

Manage any concomitant constipation

There are many situations in which nocturia cannot be improved



Should urologists manage nocturia?

- Inherent presumption that urologists should manage nocturia
- "If getting nowhere with treatment, review the diagnosis"
- Can urologists realistically lead on this review?
- If not, who should?

journfal homepage: www.europeanurology.com/eufocus



EUROPEAN UROLOGY FOCUS xxx (2022) xxx



Nocturia Is an Orphan Symptom Seeking Caring Specialties Willing To Adopt

Marcus J. Drake a,b,*, Jonathan Rees , Emily J. Henderson d,e

Drake MJ et al. Eur Urol Focus 2022;8:1-3

Nocturia conclusions

- No one specialty covers all the potential contributors for nocturia
- Even specialists may not know how conditions they manage could influence urine production
- Five SR/ consensus statements
- Overarching guideline

Net Impact Project Nocturia Guidance for GPs & primary care professionals

Austen El-Osta & Eva Riboli-Sasco Self-Care Academic Research Unit (SCARU) Imperial College London Professor Marcus Drake
Department of Surgery and Cancer
Imperial College London


NET ImpACT

Nocturia may be present if the rate of urine production by the kidneys is increased, either at night or all the time

Nocturia may be driven by **problems in several body systems** affecting urine production or sleep quality

There may be **no clear reason** for an individual patient experiencing nocturia, or it can be **multifactorial**

PLANET diagram: Assessment of Nocturia



How to assess Nocturia?

Review of the patient's **medical history & physical examination** are essential to assess the potential cause(s) of nocturia.

However, they should be supplemented with the following resources...








Resource 1: Nocturia Patient Questionnaire

Option 1 (Recommended)

Fill in during the consultation by asking the questions directly to the patient




Option 2

Print or send to the patient for them to fill in at home

Nocturia Patient Questionnaire – Interpretation guidance

The patient's
responses can
guide the
identification of the
medications &
body system(s)
causing nocturia



Sleep disorder

Renal

Cardiovascular


Neurological


Urological


Endocrine

Resource 2: Modified ICIQ Bladder Diary


The Bladder Diary must be filled at home by the patient during 3 consecutive days







Modified ICIQ Bladder Diary – Interpretation guidance



A completed Bladder Diary can help you:

- Identify nocturia episodes
- Identify the fluid contributions to nocturia
- Diagnose polyuria & nocturnal polyuria
- Assess whether the patient has an overactive bladder

Referrals

Referral to urology is inappropriate if the nocturia is due to a nonurological medical problem affecting urine production or sleep

Referrals to secondary care should be in line with guidance for the causative condition



NET ImpACT considerations

- Patient self-care can make a big difference for some, but not all
- If nocturia isn't bothersome, don't investigate in detail or aim to treat
- Some causes of nocturia cannot be treated effectively or safely

```
2010 Oxybutynin 5 mg
2011
      Tamsulosin 400 mcg
2011
      Finasteride 5 mg (4 months)
2012
      Indapamide 2.5 mg
2012
      Desmopressin 200 mcg x 2
2013 Furosemide 20 mg
2013 Solifenacin 5 mg
2013
     Fesoterodine 4mg
      Furosemide 20 mg (again)
2014
2014
     Trospium Chloride 60mg
2014
      Mirabegron 50mg
```

Routine care arm

- History/ Exam
- Symptom score
- Urinalysis
- Flow rate
- Bladder diary

Urodynamics arm

• Routine care tests + urodynamics



EUROPEAN UROLOGY 78 (2020) 701-710


Platinum Priority – Voiding Dysfunction Editorial by Gopal H. Badlani on pp. 711–712 of this issue



Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals


Marcus J. Drake a,b,* , Amanda L. Lewis c,d , Grace J. Young c,d , Paul Abrams b , Peter S. Blair c,d , Christopher Chapple e , Cathryn M.A. Glazener f,† , Jeremy Horwood c,d , John S. McGrath g , Sian Noble d , Gordon T. Taylor h , J. Athene Lane c,d

IPSS scores after surgery



BASELINE ASSESSMENT

PREDICTING SURGERY OUTCOME FOR MALE LUTS



Conclusions

- "LUTS" might be a misleading term for increased frequency and/or nocturia- urology may not be suitable
- History, symptom score and bladder diary can suggest issues of fluid handling and sleep disturbance
- NET ImpACT resources for assessing people with nocturia to help consider a range of influence
- Self care; the TRIUMPH booklet for men with LUTS shows sustained reduction in LUTS vs standard care

https://www.imperial.ac.uk/department-surgery-cancer/research/surgery/groups/functional-urology/